| アブストラクト | BACKGROUND: Although appendicitis is one of the most common surgical emergencies and is related to immune function, its relation to multiple sclerosis (MS) disease-modifying therapies (DMTs) is unclear. OBJECTIVE: To determine which, if any, MS DMTs are associated with disproportionally high appendicitis reporting using real-world data from the FDA Adverse Event Reporting System (FAERS). RESULTS: We identified 965 reports of appendicitis associated with MS DMTs. A pooled analysis of all DMTs showed disproportionately high appendicitis reporting compared to all other FAERS medications (reporting odds ratio, 2.83; 95% confidence interval, 2.63-3.06; chi (Bhangu et al., 2015), 787.54). Ocrelizumab, ofatumumab, natalizumab, alemtuzumab, dimethyl and diroximel fumarate, cladribine, and peg- and interferon beta-1a all individually exhibited disproportionally high appendicitis reporting. CONCLUSION: Patient counseling on early appendicitis warning signs and indications for urgent evaluation may be warranted for people with MS on DMTs. |
|---|
| ジャーナル名 | Multiple sclerosis and related disorders |
|---|
| Pubmed追加日 | 2026/3/6 |
|---|
| 投稿者 | Balshi, Alexandra; Esser, Madelyn; Dempsey, John P; Baber, Ursela; Sloane, Jacob A |
|---|
| 組織名 | Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical;School, Boston, MA, USA. Electronic address: alexandra_balshi@hms.harvard.edu.;School, Boston, MA, USA.;School, Boston, MA, USA; Norton College of Medicine, SUNY Upstate Medical;University, Syracuse, NY, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41785834/ |
|---|
